Executive Summary
This week's digest highlights: For single-level TLIF procedures, P-15 peptide-enhanced bone graft demonstrates superior composite clinical success compared to autograft, offering a viable alternative in spine surgery. In pediatric H3 G34-mutant diffuse hemispheric gliomas, MGMT protein expression assessment is critical for prognosis, and ensuring adequate radiation field coverage is essential due to predominantly...
Owen briefs you on what matters in this week's digest.
Think chief-resident chalk talk: what matters, what changes practice, and where to spend your reading time.
Endovascular / Vascular
Association of baseline infarct size, reperfusion grade and intracranial hemorrhage in patients undergoing thrombectomy.
Research • Endovascular / Vascular • Journal of neurointerventional surgery • 2026-02-16
In thrombectomy patients, assess baseline ASPECTS to contextualize post-reperfusion hemorrhage risk: low ASPECTS with high eTICI may warrant closer monitoring.
OIn patients with large baseline infarcts (low ASPECTS), achieving high-grade reperfusion paradoxically increases the risk of any intracranial hemorrhage, so monitor these patients closely post-procedure, though this finding did not affect symptomatic hemorrhage rates.
Study snapshot
Design
Randomized trial (ESCAPE-NA1) retrospective analysis
Population
Patients undergoing thrombectomy in the ESCAPE-NA1 trial
Intervention
Thrombectomy with assessment of reperfusion status (eTICI score)
Comparator
None (single-arm analysis of associations)
Primary outcome
Association of ASPECTS and eTICI on post-treatment intracranial hemorrhage
Why it matters
Previously, we knew that successful reperfusion after thrombectomy improves outcomes but may increase hemorrhage risk. This study adds that the relationship between reperfusion and hemorrhage depends on baseline infarct size: reperfusion reduces hemorrhage risk in patients with small baseline infarcts (high ASPECTS) but increases it in those with large baseline infarcts (low ASPECTS). Clinicians should now consider baseline ischemic extent when weighing reperfusion benefits against hemorrhage risks, though this did not translate to symptomatic hemorrhage differences.
Practice change
Confirms current practice of monitoring for hemorrhage post-thrombectomy, but may support closer imaging follow-up in patients with low ASPECTS and successful reperfusion.
More context
Key details
- Retrospective analysis of ESCAPE-NA1 randomized trial data.
- Assessed interaction between baseline ASPECTS and final eTICI score on post-treatment hemorrhage.
- Any intracranial hemorrhage occurred in 34.2% of patients.
- Marginal probabilities showed increased hemorrhage risk with low ASPECTS and increasing eTICI scores.
- Association reversed in patients with small baseline ischemic changes and successful reperfusion.
- No significant association found with symptomatic intracranial hemorrhage or parenchymal hematoma.
High-yield
In thrombectomy patients, reperfusion reduces hemorrhage risk with small baseline infarcts (high ASPECTS) but increases it with large baseline infarcts (low ASPECTS), though symptomatic hemorrhage rates remain unaffected.
Clinical context
Better reperfusion status results in smaller infarct volumes and better outcomes after thrombectomy. However, if large tissue volumes are already infarcted at baseline, reperfusion might also increase the risk of intracranial hemorrhage.
Limitations
Retrospective analysis of trial data may introduce selection bias despite randomization.Findings are based on imaging-defined hemorrhage rather than clinically symptomatic events.
Methodological critique
Retrospective analysis of randomized trial data limits causal inference for the observed interactions.
Teaching pearl
When reviewing post-thrombectomy imaging, remember that a high eTICI score in a patient with a low ASPECTS may signal higher hemorrhage risk—check the 24-hour CT closely, but don't panic unless it's symptomatic.
Funding and COI
Not stated
Tumor / Skull Base
Pediatric H3 G34-mutant diffuse hemispheric glioma: clinical, imaging and molecular prognostic factors, MGMT expression, and temozolomide response.
Research • Tumor / Skull Base • Acta neuropathologica • 2026-03-02
In pediatric H3 G-mutant DHG, prioritize MGMT protein expression assessment and ensure adequate radiation field coverage, as most recurrences are local.
OIn pediatric H3 G34-mutant DHG, MGMT protein expression (not promoter methylation) is the key prognostic biomarker, and local radiation field coverage is critical as most recurrences are in-field.
Study snapshot
Design
Retrospective multicenter cohort study
Population
Pediatric patients with newly diagnosed H3 G34-mutant diffuse hemispheric glioma
Intervention
Evaluation of clinical, imaging, molecular features, and treatments (surgery, radiation, temozolomide)
Comparator
None (descriptive and correlative analysis)
Primary outcome
Identification of prognostic factors and patterns of treatment failure
Why it matters
Before this study, pediatric H3 G34-mutant diffuse hemispheric glioma (DHG) had limited clinical data, with unclear prognostic factors and temozolomide response. This study adds the largest pediatric cohort to date, showing that MGMT expression (not promoter methylation) correlates with survival, and most failures occur within the radiation field. Clinicians should now focus on MGMT protein expression and consider radiation field coverage in treatment planning.
Practice change
Could consider incorporating MGMT protein expression testing into the diagnostic workup for pediatric H3 G34-mutant DHG to better inform temozolomide use.
More context
Key details
- Retrospective multicenter cohort study of pediatric patients with H3 G34-mutant DHG.
- Assessed clinical, imaging, and molecular features, including MGMT expression and promoter methylation.
- MGMT expression, not promoter methylation, correlated with survival outcomes.
- Most treatment failures occurred within the high-dose radiation field.
- Surgery and temozolomide use were evaluated for associations with outcomes.
- Included whole genome, exome, transcriptome, and methylation array analyses.
- Study aimed to identify molecular prognostic markers and patterns of treatment failure.
High-yield
In pediatric H3 G-mutant DHG, MGMT protein expression correlates with survival, not promoter methylation, and most recurrences are within the high-dose radiation field.
Clinical context
Pediatric-type diffuse high-grade gliomas (pHGGs) are molecularly diverse and fatal CNS tumors. Nearly 30% of pHGGs occurring in the cerebral hemispheres of older adolescents and young adults have H3 G34 mutations.
Limitations
Retrospective design with potential selection bias and heterogeneous treatment regimens.Small sample size (n=36) limits statistical power for subgroup analyses.
Methodological critique
Retrospective design and small cohort size limit generalizability and ability to establish causal relationships.
Teaching pearl
For pediatric DHG cases, order MGMT immunohistochemistry alongside methylation testing—the protein expression might tell you more about temozolomide sensitivity than the promoter status alone.
Funding and COI
Not stated
Spine
P-15 Peptide Enhanced Bone Graft in Transforaminal Lumbar Interbody Fusion: A Randomized, Controlled, Investigational Device Exemption Study Demonstrating Improved Composite Clinical Success.
Research • Spine • Spine • 2025-12-19
For single-level TLIF, consider P- peptide-enhanced bone graft as an alternative to autograft given its superior composite clinical success.
OP-15 peptide graft shows promising fusion and clinical outcomes in TLIF, but given the composite endpoint's complexity and the study's industry sponsorship, interpret its superiority over autograft with cautious optimism until replicated in broader practice.
Study snapshot
Design
Prospective, multicenter, single-blind, randomized controlled trial
Population
Skeletally mature adults (22-80 years) with single-level degenerative disc disease undergoing TLIF
Intervention
P-15 peptide-enhanced bone graft (P-15L)
Comparator
Local autologous bone graft
Primary outcome
Month 24 composite clinical success (CCS)
Why it matters
Local autograft has been the standard for bone graft in TLIF but carries harvest morbidity and variable fusion rates. This study demonstrates that P-15 peptide-enhanced bone graft is superior to autograft in composite clinical success at 24 months, with comparable safety. Surgeons could consider P-15L as an alternative to autograft for single-level TLIF.
Practice change
May support using P-15 peptide-enhanced bone graft as an alternative to autograft in TLIF procedures, given its superior composite success rates.
More context
Key details
- Prospective, multicenter, single-blind, randomized controlled trial.
- Patients underwent single-level TLIF (L2-S1) for degenerative disc disease.
High-yield
P- peptide-enhanced bone graft achieved 55.5% composite clinical success versus 37.5% for autograft in TLIF, demonstrating superiority with similar device-related safety.
Clinical context
Local autologous bone graft is the gold standard for bone graft in TLIF but has limitations such as harvest site morbidity and variable fusion rates.
Limitations
Single-blind design may introduce bias in patient-reported outcomes.Higher procedure-related AE rate in the investigational group warrants careful consideration of surgical technique.
Methodological critique
Single-blind design could lead to bias in patient-reported outcomes like ODI, though radiographic assessments were blinded.
Teaching pearl
In single-level TLIF, P-15 graft achieved 25.8% higher fusion rates than autograft—when reviewing postoperative CTs, look for bridging bone at 24 months as this was the key radiographic success criterion.
Funding and COI
Not stated
Functional
Postoperative Weight Gain and Body Composition in DBS Patients: Associations with IPG Recharge Efficiency.
Research • Functional • Stereotactic and functional neurosurgery • 2026-03-04
Consider discussing with male DBS patients that increased body fat may slow IPG recharge times.
OIn male DBS patients, counsel that increased body fat may slow IPG recharge times, though this is based on a small, low-quality study.
Study snapshot
Design
Cross-sectional study
Population
Thirty people with DBS
Intervention
Standardized charging protocol to measure IPG recharge rate
Comparator
None (correlational analysis)
Primary outcome
Relationship between biometric parameters and IPG charge rate
Why it matters
Weight gain after DBS implantation has been reported, but its impact on device function was unclear. This study suggests a correlation between increased body fat and slower IPG recharge rates in male DBS patients. Clinicians may consider counseling patients on postoperative weight management to potentially optimize device performance.
Practice change
May support discussing weight management with male DBS patients to potentially optimize device recharge efficiency.
More context
Key details
- Cross-sectional study of 30 DBS patients
- Standardized charging protocol used to measure battery charge acquisition rate
- Biometric data included weight, BMI, and body fat measurements
- Strong negative correlation found in males (r=-0.6)
- No significant correlation found in female participants despite higher body fat levels
High-yield
In male DBS patients, higher body fat correlates with slower IPG recharge rates (r=-, p=0.02), suggesting adipose tissue depth may impede charging efficiency.
Clinical context
Weight gain has been reported following DBS implantation, and anecdotal evidence suggests difficulties recharging batteries in patients with larger body mass. The relationship between body mass and charge times had not been systematically investigated.
Limitations
Cross-sectional design limits causal inference between weight gain and DBSSmall sample size and exploratory nature require validation in larger cohorts
Methodological critique
Cross-sectional design prevents determination of causality between DBS and weight gain.
Teaching pearl
When male DBS patients ask about recharge times, remember that body fat correlates with slower charging (r=-0.6, p=0.02), so consider discussing weight management as part of device optimization.
Funding and COI
Not stated
General Neurosurgery
Safety and efficacy of eslicarbazepine acetate for seizure prevention in patients with stroke at high risk of developing post-stroke epilepsy: a proof-of-concept, phase 2a, randomised, double-blind, placebo-controlled antiepileptogenesis trial.
Research • General Neurosurgery • The Lancet. Neurology • 2026-03
Do not prescribe eslicarbazepine acetate for post-stroke seizure prevention based on current evidence.
OThis negative trial was underpowered, so while eslicarbazepine should not be used for post-stroke seizure prevention, its wide confidence interval means we still don't know if it could help or harm.
Study snapshot
Design
Phase 2a, double-blind, randomized, placebo-controlled trial
Population
Adults with acute ischemic stroke or intracerebral hemorrhage at high risk of developing unprovoked seizures (SeLECT score ≥5 or CAVE score ≥2)
Intervention
Eslicarbazepine acetate 800 mg/day orally for 30 days
Comparator
Placebo
Primary outcome
Proportion of patients with first unprovoked seizure, death, or discontinuation within 6 months after randomization
Why it matters
Previous preclinical studies suggested eslicarbazepine acetate might have antiepileptogenic properties, but clinical evidence was lacking. This phase 2a trial found no significant difference in preventing post-stroke seizures compared to placebo, though it was underpowered. Clinicians should not yet adopt eslicarbazepine for seizure prevention after stroke, but the study demonstrates feasibility for future adequately powered trials.
Practice change
Confirms current practice of not using eslicarbazepine for post-stroke seizure prevention.
More context
Key details
- Phase 2a, double-blind, randomized, placebo-controlled trial
- 125 patients with acute ischemic stroke or intracerebral hemorrhage at high seizure risk
High-yield
Eslicarbazepine acetate showed no significant benefit over placebo for preventing post-stroke seizures at months ( vs , OR , 95% CI -, p=) in this underpowered trial.
Clinical context
Eslicarbazepine acetate is an antiseizure medication that has shown potential antiepileptogenic effects in preclinical models of epilepsy. This study aimed to investigate whether it could prevent or reduce incidence of unprovoked seizures after acute ischemic stroke or intracerebral hemorrhage.
Limitations
Underpowered due to slow recruitment and COVID-19 pandemic impactWide confidence intervals preclude definitive conclusions about treatment effect
Methodological critique
The trial was underpowered due to slow recruitment and COVID- pandemic, producing inconclusive results.
Teaching pearl
When evaluating negative trials, note that this study's wide confidence interval (0.31-1.40) means we cannot rule out a clinically meaningful benefit or harm, highlighting the importance of adequate sample size in prevention trials.
Funding and COI
Funding: BIAL
Basic Science
CXCL1: a novel therapeutic target to increase aneurysm healing after coil embolization.
Research • Basic Science • Frontiers in stroke • 2026-02-10
While not yet clinically applicable, CXCL represents a promising therapeutic target for adjunctive pharmacotherapy to reduce aneurysm recanalization after coiling.
OTargeting CXCL1 to improve aneurysm healing after coiling is a promising preclinical concept, but its clinical relevance remains speculative until validated in human studies.
Study snapshot
Design
Randomized, blinded preclinical study in a murine aneurysm coiling model
Population
Female and male C57BL/6 mice (8-12 weeks) with surgically created saccular carotid artery aneurysms
Intervention
Systemic CXCL1 neutralization via intraperitoneal injections of neutralizing antibody
Comparator
Isotype-matched IgG control injections
Primary outcome
Percentage of intrasaccular tissue ingrowth measured histologically 21 days post-coiling
Why it matters
Recanalization after aneurysm coiling remains a significant clinical problem. This preclinical study suggests CXCL1 neutralization may enhance tissue ingrowth and improve aneurysm healing after coil embolization. While not yet ready for clinical application, these findings could support future development of adjunctive pharmacologic therapies to reduce recanalization rates.
Practice change
Confirms current practice; preclinical findings may support future development of adjunctive pharmacologic therapies targeting inflammatory mediators like CXCL1.
More context
Key details
- Preclinical study using a murine carotid artery aneurysm coiling model
- CXCL1 expression was significantly higher in aneurysms compared to normal carotid arteries
- Systemic CXCL1 neutralization via intraperitoneal injections of neutralizing antibody
High-yield
Systemic CXCL neutralization for - days increased tissue ingrowth by approximately - percentage points in a murine aneurysm coiling model, suggesting a potential therapeutic target to improve healing.
Clinical context
Up to 26.3% of coiled aneurysms demonstrate recanalization requiring retreatment. The healing process after coil embolization involves inflammatory cell infiltration and fibrous scar formation, but specific inflammatory pathways are not fully understood.
Limitations
Preclinical mouse model may not fully replicate human aneurysm pathophysiology or healing responsesIntraperitoneal administration route subjects antibodies to first-pass metabolism, potentially affecting bioavailability
Methodological critique
The intraperitoneal administration route subjects antibodies to first-pass metabolism, which may affect therapeutic bioavailability.
Teaching pearl
In this murine model, CXCL1 neutralization for at least 14 days—but not 7 days—significantly increased tissue ingrowth after coiling, suggesting treatment duration is critical when targeting this inflammatory pathway.
Funding and COI
Not stated
Trials to Know
Large Artery Occlusion Treated in Extended Time With Mechanical Thrombectomy Trial
Trial • Trials to Know • ClinicalTrials.gov • 2026-03-06
Why it matters
This recruiting trial may offer eligible patients access to novel interventions.
A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
Trial • Trials to Know • ClinicalTrials.gov • 2026-03-06
Why it matters
This recruiting trial may offer eligible patients access to novel interventions.
From the Preprint Wire
Virtual Aerobic Exercise Improves Cognition in Mild TBI: Pilot RCT
Preprint • From the Preprint Wire • medrxiv • 2026-02-23
Why it matters
This preprint presents a promising non-pharmacological approach for cognitive rehabilitation in mild traumatic brain injury (mTBI) patients, addressing a significant clinical gap. For neurosurgeons managing mTBI sequelae, a virtual, symptom-guided exercise protocol could offer a scalable adjunct to standard care. However, as an unreviewed preprint, these findings require cautious interpretation until validated through peer review.
More context
Key details
- 75% completion rate with 94.2% session adherence and no adverse events, supporting feasibility and safety of virtual delivery
- Aerobic exercise group showed large effect size improvements in executive function (Trail Making Test B-A) compared to balance controls
- Secondary benefits included reduced sleep disturbances in the aerobic group, suggesting broader neurocognitive impacts
GLP-1 Receptor Agonists vs. Other Antiobesity Medications for Cardiovascular Risk Reduction in Overweight/Obesity Without Diabetes
Preprint • From the Preprint Wire • medrxiv • 2026-02-20
Why it matters
This preprint, which has NOT undergone peer review, addresses a critical question in preventive neurosurgery: whether GLP-1 receptor agonists (like semaglutide) offer superior cardiovascular protection compared to other antiobesity medications in patients with overweight/obesity and prior cardiovascular disease but no diabetes. Given the high prevalence of obesity and its link to recurrent stroke and other cerebrovascular events, neurosurgeons managing secondary prevention may find these comparative effectiveness data relevant for optimizing medical therapy in at-risk populations.
More context
Key details
- Study included over 120 million patients from the Truveta EHR database, with 35,240 in the bupropion-naltrexone vs. GLP-1 RA comparison and 27,051 in the phentermine-topiramate vs. GLP-1 RA comparison.
- Primary endpoint was time to first MACCE (stroke or myocardial infarction) in adults with BMI ≥27 kg/m² and prior cardiovascular disease but no diabetes.
- After propensity score-overlap weighting, GLP-1 RA showed a 39% lower hazard of MACCE vs. phentermine-topiramate, with an adjusted absolute rate difference of 0.98 events per 1000 person-years.